Podcasts about gynecology

IUDs are under the umbrella of long-acting, reversible contraceptives, and they’re the oldest one of these in use today. Research: Baldauf, P et al. “A Report on the Hysteroscopic Removal of a Gräfenberg Ring After Almost Fifty Years in Utero.” Geburtshilfe und Frauenheilkunde vol. 74,11 (2014): 1023-1025. doi:10.1055/s-0034-1383130. https://pmc.ncbi.nlm.nih.gov/articles/PMC4245252/ Case Western Reserve University. “Intrauterine device (IUD).” https://artsci.case.edu/dittrick/online-exhibits/history-of-birth-control/contraception-in-america-1950-present-day/intrauterine-device-iud/ Cooper, James Fryer. “Technique of contraception: the principles and practice of anti-conceptional methods.” Day-Nichols Inc., Publishers. 1928, 1930. https://archive.org/details/techniqueofcontr0000jame/ Corbett, Megan and Brandy Bautista. “A History: The IUD.” Reproductive Health Access Project. 3/20/2024. https://www.reproductiveaccess.org/2024/03/a-history-the-iud/ Curtis, Kathryn M. et al. “U.S. Selected Practice Recommendations for Contraceptive Use, 2024.” Centers for Disease Control. 8/8/2024. https://www.cdc.gov/mmwr/volumes/73/rr/rr7303a1.htm Dickinson, Robert L. et al. “Contraception: A Medical Review of the Situation.” American Journal of Obstetrics and Gynecology 1924-11: Vol 8 Iss 5. https://archive.org/details/in.ernet.dli.2015.50850/page/n585/ Edwards, Baylee A., "Ernst Gräfenberg (1881–1957)". Embryo Project Encyclopedia ( 2022-11-17 ). ISSN: 1940-5030 https://hdl.handle.net/10776/13358 Fallas, Rebecca and Helen King. “IUD or not IUD? Did the Hippocratics invent the first intrauterine device?. Mistaking Histories. 7/18/2017. https://mistakinghistories.uk/2017/07/18/iud-or-not-iud-did-the-hippocratics-invent-the-first-intrauterine-device/ Fotinos, Diane J. “Gold Stemmed Pessaries: A Shadow of the Past.” UT Health. 9/11/2019. https://library.uthscsa.edu/2017/09/gold-stemmed-pessaries-a-shadow-of-the-past/ Goldstuck, Norman D. “Reducing Barriers to the use of the Intrauterine Contraceptive Device as a Long Acting Reversible Contraceptive.” African Journal of Reproductive Health / La Revue Africaine de la Santé Reproductive, December 2014, Vol. 18, No. 4 (December 2014). Via JSTOR. https://www.jstor.org/stable/24362040 Goodhue PA. The Dalkon Shield debate. Conn Med. 1983 Mar;47(3):138-41. PMID: 6851548. Haubacher, David. “The Checkered Past and Bright Future of Intrauterine Contraception in the United States.” Perspectives on Sexual and Reproductive Health , Mar. - Apr., 2002. Via JSTOR. https://www.jstor.org/stable/3030213 Homei, Aya. “Why did the Japanese Government take so long to approve the intrauterine contraceptive device?.” Reproductive biomedicine & society online vol. 6 45-54. 16 Oct. 2018, doi:10.1016/j.rbms.2018.09.002 Hubacher, David. “The Checkered History and Bright Future of Intrauterine Contraception In the United States.” Perspectives on Sexual and Reproductive Health. Vol. 34, Issue 2. https://www.guttmacher.org/journals/psrh/2002/03/checkered-history-and-bright-future-intrauterine-contraception-united-states Hutchings, Jane E. et al. “The IUD After 20 Years: A Review of Worldwide Experience.” International Family Planning Perspectives, Vol. 11, No. 3 (Sep., 1985). https://www.jstor.org/stable/2947998 Jones, R. W., et al. “Clinical Experience With The Dalkon Shield Intrauterine Device.” The British Medical Journal, vol. 3, no. 5872, 1973, pp. 143–45. JSTOR, http://www.jstor.org/stable/25420726. Accessed 5 Mar. 2026. Klapperich, Catherine M. “From the Dalkon Shield to Britney Spears’ IUD: Why Diverse Teams Need to Be Involved in Contraceptive Design.” The Brink. Boston University. 7/1/2021. https://www.bu.edu/articles/2021/from-the-dalkon-shield-to-britney-spears-iud-why-diverse-teams-need-to-be-involved-in-contraceptive-design/ Lopes-Garcia, E. A., Carmona, E. V., Monteiro, I., & Bahamondes, L. (2023). Assessment of pain and ease of intrauterine device placement according to type of device, parity, and mode of delivery. The European Journal of Contraception & Reproductive Health Care, 28(3), 163–167. https://doi.org/10.1080/13625187.2023.2189500 Margulies, Lazar. “History of Intrauterine Devices.” Bull. N. Y. Acad. Med. Vol. 51, No. 5, May 1975. Museum of Contraception and Abortion. “Tenrei Ota (1900-1985).” https://muvs.org/en/topics/pioneers/tenrei-ota-1900-1985-en/ Oppenheimer, W.. “Prevention of pregnancy by the graefenberg ring method.” American Journal of Obstetrics & Gynecology, Volume 78, Issue 2, 446 – 454. https://www.ajog.org/article/0002-9378(59)90203-0/abstract Peipert, Jeffrey F. “Lippes loop and the first IUDs: lessons from a bygone era.” American Journal of Obstetrics & Gynecology, Volume 219, Issue 2, 127 – 128. https://www.ajog.org/article/S0002-9378(18)30488-5/fulltext Peipert, Jeffrey F. “Lippes loop and the first IUDs: lessons from a bygone era.” American Journal of Obstetrics & Gynecology, Volume 219, Issue 2, 127 – 128 . https://www.ajog.org/article/S0002-9378(18)30488-5/fulltext Thiery, M. “Pioneers of the intrauterine device.” The European Journal of Contraception and Reproductive Health Care. Volume 2, Number 1, March 1997. The Parthenon Publishing Group International Publishers. Thomsen, Russel J. “An Atlas of Intrauterine Contraception.” Hemisphere Publishing Company. 1982. Tietze, Christopher and Sarah Lewit. “Intra-Uterine Contraceptive Devices: Proceedings of the Conference, April 30-May 1, 1962, New York City.” Exerpta Medica Foundation. Willingham, Emily. “A ‘Simple’ Piece of Plastic.” American Scientist. May-June 2012. https://www.americanscientist.org/article/a-simple-piece-of-plastic World Health Organization. “Selected practice recommendations for contraceptive use.” Fourth Edition. https://iris.who.int/server/api/core/bitstreams/582c8182-f4b1-406b-b5e7-d81c1870df93/content See omnystudio.com/listener for privacy information.

In this special crossover episode, Tiny Matters welcomes Alexis Pedrick, host of Distillations from the Science History Institute. You'll hear the Distillations episode “The Mothers of Gynecology” — a powerful investigation into the racist origins of gynecology and the ongoing maternal health care crisis that disproportionately affects Black mothers. Through interviews with historians, clinicians, midwives, doulas, and public health researchers, the episode traces how racist myths about Black bodies — especially beliefs about pain tolerance — continue to shape medical care and outcomes. Following the episode, we unpack some of what you'll hear, from the horrific exploitation of enslaved women by J. Marion Sims, to modern-day disparities that affect even the wealthiest, most famous Black mothers, including Beyoncé and Serena Williams.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Neuraxial analgesia (epidural or spinal) combined withtocolytic therapy is the pain control method that best increases the success rate of external cephalic version (ECV), according to the ACOG's PB 221. However, some patients may be reluctant to use regional anesthesia and may askabout IV analgesia. A new study in the AJOG (released as an ePub on March 5, 2026) provides some insights that may be helpful for patient consultation. These investigators compared the success of external cephalic version, modes of delivery, maternal pain, and complications using three strategies: intravenous analgesia with remifentanil, epidural anesthesia, and a stepwise approach in which epidural anesthesia was administered only if intravenous analgesia was unsuccessful. Listen in for details.1.     ACOG PB 2212.     Aiartzaguena, Amaia et al. Comparativeeffectiveness of intravenous remifentanil, epidural anesthesia and a two-stepanalgesic approach for external cephalic version: a large prospectivesingle-center cohort study. American Journal of Obstetrics & Gynecology,Volume 0, Issue 03.     Hao Q, Hu Y, Zhang L, et a l. A SystematicReview and Meta-Analysis of Clinical Trials of Neuraxial, Intravenous, andInhalational Anesthesia for External Cephalic Version. Anesthesia andAnalgesia. 2020. 4.     Wilson MJA, MacArthur C, Hewitt CA, et al.5.     Intravenous Remifentanil Patient-ControlledAnalgesia Versus Intramuscular Pethidine for Pain Relief in Labour (RESPITE):An Open-Label, Multicentre, Randomised Controlled Trial. Lancet. 2018.

The ACOG 2025 guideline specifically recommends either oral or vaginal misoprostol for cervical ripening; it does not include buccal administration among its endorsed routes. With the rising rates of both obesity and labor induction, understanding the optimal agents for induction in obese patients is crucial. In a new study released ahead of print on March 4, 2026, in the AJOG, investigators from Indianapolis released findings from a secondary analysis of the IMPROVE trial (2019, AJOG) looking at the effect of obesity on buccal vs vaginal doses of misoprostol for cervical ripening. Listen in for details.1. Haas DM, Daggy J, Flannery KM, Dorr ML, Bonsack C, Bhamidipalli SS, Pierson RC, Lathrop A, Towns R, Ngo N, Head A, Morgan S, Quinney SK. A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial. Am J Obstet Gynecol. 2019 Sep;221(3):259.e1-259.e16. doi: 10.1016/j.ajog.2019.04.037. Epub 2019 May 7. PMID: 31075246; PMCID: PMC7692024.2. ACOG July 2025: Cervical Ripening in Pregnancy, ACOG Clinical Practice Guideline No. 93. Bynarowicz, Taylor M. et al. The impact of body mass index on misoprostol dosing for labor induction: a comparison of vaginal and buccal dosage formsAmerican Journal of Obstetrics & Gynecology, Volume 0, Issue 0: https://www.ajog.org/article/S0002-9378(26)00126-2/fulltext4. Etrusco A, Sfregola G, Zendoli F, et al. Effect of Maternal Age and Body Mass Index on Induction of Labor Using Oral Misoprostol in Late-Term Pregnancies: A Retrospective Cross-Sectional Study. Gynecologic and Obstetric Investigation. 2024. 5. Prostaglandin Versus Mechanical Dilation and the Effect of Maternal Obesity on Failure to Achieve Active Labor: A Cohort Study.6. Beckwith L, Magner K, Kritzer S, Warshak CR. The Journal of Maternal-Fetal & Neonatal Medicine : The Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2017.

Dr. Mary Rosser, obstetrician gynecologist and director of Fazzalari Women's Health at NewYork-Presbyterian The One and Columbia, joins us to explain how the endocrine system functions and how external chemicals can disrupt hormonal signals that influence metabolism, fertility, cancer risk, and long-term health. She details the most common sources of endocrine disruptors — including plastics, personal care items, cleaning products, and pesticides — and shares clear, manageable strategies for reducing everyday exposure. Dr. Rosser's guidance empowers listeners to make small, sustainable changes that can help protect hormonal well‑being.   Chapters: 00:00:00 — Understanding Hormones and Endocrine Disruptors 00:05:01 — Health Effects Linked to Endocrine Disruptors 00:09:55 — Everyday Sources and How to Reduce Exposure 00:17:28 — Can the Body Recover? Practical Steps and Final Takeaways   Key Topics Covered What hormones are and how the endocrine system works What endocrine disruptors are and how they interfere with hormone signaling How endocrine disruptors enter the body (skin, food, air) Health impacts: metabolism, fertility, cancer risk, and chronic conditions Common sources of disruptors (plastics, BPA, phthalates, cosmetics, cleaning products, pesticides, microplastics) Practical ways to reduce exposure in daily life How to monitor hormone health and when to talk to a doctor The body's ability to recover once exposure is reduced   Takeaway Message This episode empowers listeners to understand how everyday chemicals can interfere with the body's delicate hormonal system — and shows that small, practical changes in the products we use and the foods we choose can meaningfully reduce exposure.   Expert Guest Dr. Mary L. Rosser, M.D., Ph.D., NCMP is an obstetrician gynecologist and the director of Fazzalari Women's Health at NewYork-Presbyterian The One and Columbia. She is the Richard U. and Ellen J. Levine Assistant Professor of Women's Health (in Obstetrics and Gynecology) at Columbia University Vagelos College of Physicians & Surgeons. She joined the faculty of Obstetrics and Gynecology at Columbia University in April 2018 to provide routine gynecology care and to further develop a comprehensive well-woman program. She has been a practicing obstetrician gynecologist for more than 20 years, starting in private practice and then joining the faculty at Montefiore Medical Center in Bronx, NY. While at Montefiore, she created, launched, and led the forty-person Division of General Obstetrics and Gynecology. Dr. Rosser received her undergraduate degree at Emory University and a Ph.D. in Endocrinology at the Medical College of Georgia. She attended Wake Forest University School of Medicine and completed her residency at Emory University. She is also a NAMS Certified Menopause Practitioner, able to provide high-quality care for patients at menopause and beyond. Primary care and heart disease in women have always been areas of focus for Dr. Rosser. She conducted basic science research on heart disease during graduate school and was the Chair of the "Women & Heart Disease Physician Education Initiative" for District II of the American College of Obstetrics & Gynecology. She continues to conduct clinical studies around patient awareness and understanding of heart disease and well-woman care. Dr. Rosser serves on the Medical Leadership Team of the Go Red for Women movement of the American Heart Association and she is ACOG's liaison to the American College of Cardiology.  

For preterm prelabor rupture of membranes, the standard protocol for latency augmentation has remained IV amoxicillin and erythromycin for 2 days, followed by oral amoxicillin and erythromycin for 5 additional days. Nonetheless, azithromycinhas largely replaced erythromycin in PPROM management due to supply shortages and tolerability.  Previous retrospective studies (2019) have found no difference in latency between single-dose and multi-day azithromycin regimens, but these studies did not measure actual drugconcentrations at the site of action. In that 2019 retrospective study, there was also no difference in incidence of chorioamnionitis, or neonatal outcomes when comparing different dosing regimens of the azithromycin with erythromycin, with the exception of respiratory distress syndrome being more common in the 5 day azithromycin group. However, a 2024 single-center,retrospective study from Annals Pharmacotherapy found significantly higher rates of histologic chorioamnionitis with single-dose azithromycin compared to 5-day regimens(62.6% vs 46.4%, P=0.006), despite similar latency periods. So, it's complicated. A 2025 systematic review of international guidelines found that 6 out of 17 clinical practice guidelines acknowledged uncertainty about the optimal antibiotic regimen. This was published in the AJOG. In this episode, wewill review a new publication from March 2026 in the AJOG which sought to compare the pharmacokinetic parameters of 1 g once vs 500 mg daily dosing of azithromycin in the setting of preterm prelabor rupture of membranes and simulate various dosing regimens to identify the optimal regimen that maintains amniotic fluid concentration of azithromycin over the minimum inhibitory concentration of common GU pathogens associated with intraamniotic infection orinflammation. But there is a BIG limitation. Listen in for details. 1.    Navathe R, Schoen CN, Heidari P, Bachilova S, Ward A, Tepper J, Visintainer P, Hoffman MK, Smith S, Berghella V, Roman A. Azithromycin vs erythromycin for the management of preterm premature rupture of membranes. Am J Obstet Gynecol. 2019 Aug;221(2):144.e1-144.e8. doi: 10.1016/j.ajog.2019.03.009. Epub 2019 Mar 20.PMID: 30904320.2.    Kua S, Roman A, Harbinson L, Groom K, Whitehead C. Systematic review of nationaland international clinical practice guidelines for management of preterm prelabor rupture of membranes. Am J Obstet Gynecol. 2025 Nov 22:S0002-9378(25)00866-X. 3.    Day KN, Vircks JA, Henricks CE, Reaves KM, Holmes AK, Florio KL. Latency Antibiotics in Preterm Prelabor Rupture of Membranes: A Comparison of Azithromycin Regimens. Ann Pharmacother. 2024 Mar;58(3):234-240. doi:10.1177/10600280231181135. Epub 2023 Jun 26. PMID: 38124306.4.   Boelig, Rupsa C. et al. Azithromycin in preterm prematurerupture of membranes: population pharmacokinetics and dose optimization. AmericanJournal of Obstetrics & Gynecology, March 2026.  SPONSER SITE: Visit www.perspectivemedical for more information on the Hemorrhage View C-Section Drape

Probiotics. They are often marketed as the end of all and be all for all our health issues. And they CAN do some real good. There is NO DOUBT a connection with overall heath and gut health…and NO ONE can deny that. But probiotics gets grey for some women's health issues. A new prospective, single-arm, non-blinded, multicenter study across 31 hospitals in Japan is making some pretty dramatic claims regarding oral probiotics and recurrent spontaneous preterm birth (ePUB). Can oral probiotics reduce spontaneous recurrent preterm birth? Listen in for details. 1. Prevention of Recurrent Spontaneous Preterm Delivery Using Probiotics: Results from a Prospective, Single-Arm, Multicenter Trial. PPP trial Collaborators et al.American Journal of Obstetrics & Gynecology, Volume 0, Issue 02. Grev J, Berg M, Soll R. Maternal probiotic supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2018 Dec 12;12(12):CD012519. doi: 10.1002/14651858.CD012519.pub2. PMID: 30548483; PMCID: PMC6516999.3. Jarde A, Lewis-Mikhael AM, Moayyedi P, Stearns JC, Collins SM, Beyene J, McDonald SD. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2018 Jan 8;18(1):14. doi: 10.1186/s12884-017-1629-5. PMID: 29310610; PMCID: PMC5759212.4. Othman M, Neilson JP, Alfirevic Z. Probiotics for preventing preterm labour. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD005941. doi: 10.1002/14651858.CD005941.pub2. PMID: 17253567; PMCID: PMC9006117.5. Timing of Probiotic Milk Consumption During Pregnancy and Effects on the Incidence of Preeclampsia and Preterm Delivery: A Prospective Observational Cohort Study in Norway.6. Nordqvist M, Jacobsson B, Brantsæter AL, Myhre R, Nilsson S, Sengpiel V. Timing of probiotic milk consumption during pregnancy and effects on the incidence of preeclampsia and preterm delivery: a prospective observational cohort study in Norway. BMJ Open. 2018 Jan 23;8(1):e018021. doi: 10.1136/bmjopen-2017-018021. PMID: 29362253; PMCID: PMC5780685.7. Gao Q, Sun Y, Qu Y, Li F, Li P. The effect of probiotic supplementation during pregnancy on pregnancy complications: An umbrella meta-analysis. Medicine (Baltimore). 2025 Dec 19;104(51):e46409. doi: 10.1097/MD.0000000000046409. PMID: 41430994; PMCID: PMC12727282.SPONSOR WEBSITE: Visit perspectivemedical.org to learn more about the Hemorrhage View C-Section Drape

Guest Dr. Ward McClellan and first-time co-host Dr. John G. Pierce join host Dr. Mike Chupp for Part 2 of a conversation about infertility and in vitro fertilization. As a reproductive endocrinologist, OB-GYN, and follower of Christ, Dr. McClellan brings both clinical expertise and biblical conviction to this topic. Dr. Pierce, CMDA's Vice President of Missions and Medical Education and Chair of Women's Health at LUCOM, is board-trained in both Internal Medicine and Obstetrics and Gynecology, bringing decades of clinical and academic experience to the discussion. Together with Dr. Chupp, they explore how Christian healthcare professionals can navigate the ethical complexities of IVF, uphold the dignity of every human life, and care well for couples facing infertility while remaining faithful to Christ in a rapidly evolving field of medicine.

Neither the ACOG nor SMFM recommend strict bed rest for preterm birth prevention, or nor preeclampsia. Yet tradition often conflicts with evidence. A prior 2009 survey of MFM specialists, published in the AJOG, on the use of bed rest revealed that 71% used activity restriction in their practice for arrested preterm labor, despite the majority believing it had minimal or no benefit. The authors concluded, “Because most obstetricians in our survey indicated they would prescribe bed rest believing it was associated with minimal or no benefit, it is possible that even if a randomized, prospective trial showed no benefit associated with bed rest, it would still remain a common recommendation.” This brings us to a brand new publication from the Green Journal which is an ancillary study of two randomized trials of preterm birth prevention in women with a short cervical length. These authors sought to evaluate the amount of physical activity in patients at high risk for preterm birth and pregnancy latency and preterm birth. What did they find? It is a bit shocking. Listen in for details.1. Fox, Nathan S. et al. The recommendation for bed rest in the setting of arrested preterm labor and premature rupture of membranes. American Journal of Obstetrics & Gynecology, Volume 200, Issue 2, 165.e1 - 165.e6 https://www.ajog.org/article/S0002-9378(08)00909-5/fulltext2. Sciscione, Anthony C. DO; Booker, Whitney A. for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network, Bethesda, Maryland. Activity Restriction in Pregnancy and the Risk of Early Delivery: The AWARE Study. Obstetrics & Gynecology ():10.1097/AOG.0000000000006225, February 19, 2026. | DOI: 10.1097/AOG.0000000000006225 https://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=9900&issue=00000&article=01460&type=FulltextVisit our SPONSOR's Webpage for information on the Hemorrhage View C-Section Drape: www.perspectivemedical.org

Welcome to Fertility and Sterility Roundtable, hosted by Dr. Emily Barnard and Dr. Ben Peipert! Each week, we will host a discussion with the authors of "Views and Reviews" and "Fertile Battle" articles published in a recent issue of Fertility and Sterility.  Today, we will be discussing the Fertile Battle from the February issue of Fertility and Sterility which is entitled "Should you do ultrasound monitoring and trigger for intrauterine insemination cycles? We are joined by two of the authors, Dr. Cassie Hobbs who will be taking the "pro" side in favor of ultrasound monitoring, and Dr. Lindsay Hartup, who will be arguing to do away with ultrasound monitoring.  Dr. Cassie Hobbs is a second-year Reproductive Endocrinology and Infertility fellow at the University of Pennsylvania. She completed her OB/GYN residency training at Brown University and received her medical degree from Duke University School of Medicine. She is passionate about examining disparities that exist in reproductive medicine and taking steps to make family building a more equitable process for all.  Dr. Lindsay Hartup is a Reproductive Endocrinology and Infertility fellow at Brigham and Women's Hospital. She completed medical school and Obstetrics and Gynecology residency at the University of Texas Health San Antonio. Her research interests are fertility preservation/oncofertility, assisted reproductive technology, and chronic endometritis. Read the Fertile Battle from Volume 125, Issue 2 p228-233 in the February 2026 issue View Fertility and Sterility at https://www.fertstert.org/  

Send a textIn this episode of Never Been Sicker, Michael Rubino talks with fertility specialist Dr. Robert Kiltz about why chronic illness and infertility feel more common than ever. Dr. Kiltz shares his perspective on modern nutrition advice, the role of inflammation, and why he believes animal fat, eating less often, and fasting can be powerful tools for health.They also dive into indoor air quality, mold, and how today's sealed homes and HVAC systems can trap particles and microbes, making it harder to feel your best. Dr. Kiltz explains why mindset, faith, and visualization matter, especially for women navigating infertility.

Women's health is at a pivotal moment in Ohio. From maternal care deserts and rising maternal mortality, to oncology advances and long-overdue conversations about menopause and postpartum mental health, this Columbus Metropolitan Club forum explores what our region is getting right—and where the system is still failing Ohio's women. Featuring Panelists: Jatu Boikai, Founder and CEO, Central Ohio Postpartum Extended Respite Center Dr. Kamilah Dixon, Director of the General Division of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center Dr. Shilpa Padia, Co-Medical Director of Oncology, Mount Carmel Health System Dr. Mona Prasad, System Chief, Maternal Fetal Medicine, OhioHealth Physicians Group Your host is Tracy Townsend, News Anchor and Medical Correspondent, WBNS 10TV. The presenting sponsors of CMC's long-running Optimal Health Series are Nationwide Children's Hospital, OhioHealth, and The Ohio State University Wexner Medical Center. This forum was also sponsored by Mount Carmel Health System. The presenting sponsor of the CMC livestream is The Center for Human Kindness at the Columbus Foundation. CMC's livestream partner is The Columbus Dispatch. This forum was also supported by Downtown Columbus, Inc. and The National Veterans Memorial and Museum. If you would like to keep exploring this week's forum topic, our partners at The Columbus Metropolitan Library recommend reading "The New Rules of Women's Health: Your Guide to Thriving at Any Age" by Meghan Rabbitt (2026). This forum was recorded before a live audience at the National Veterans Memorial and Museum in Columbus, Ohio on Wednesday, February 18, 2026.

We recently covered an SMFM abstract that was presented at the annual Pregnancy Meeting held in early February 2026. The authors were from my Alma Mater, UT Southwestern/Parkland Hospital. This was a well-done study comparing 162 milligrams aspirin to 81 milligrams of aspirin. The results were very encouraging! However, aspirin definitely has an awkward acumen. It would be wonderful if ALL the data just leaned in the same direction... but it doesn't! Enter our podcast family member, and my friend Alex. Alex sent me an incredible and insightful message which was a rebuttal to my Southwestern colleagues' findings. In this episode you'll hear Alex's rebuttal and clinical conundrum, and we will explain why these two seemingly paradoxical findings makes sense. Listen in for details.1. Khander, Amrin MD; Thomas, Charlene MS; Matthews, Kathy MD; Christos, Paul DrPH; Alcus, Claire BA; Alam, Tanvir BS; Bush, Leah BA; Deshmukh, Diksha BA; Chasen, Stephen T. MD; Riley, Laura E. MD; Skupski, Daniel W. MD; August, Phyllis MD, MPH; Malha, Line MD, MS. Comparison of 162 mg and 81 mg Aspirin for Prevention of Preeclampsia: A Randomized Controlled Trial. Obstetrics & Gynecology 147(1):p 87-96, January 2026. | DOI: 10.1097/AOG.0000000000006100

From diagnosis to treatment, hysteroscopy plays a pivotal role in modern gynecologic care. In this episode of BackTable OBGYN, Dr. Christina Salazar, a minimally invasive gynecologic surgeon and associate professor at Dell Medical School in Austin, Texas, joins hosts Dr. Mark Hoffman and Dr. Amy Park to discuss the value of hysteroscopy in managing complex intrauterine pathology. --- SYNPOSIS Dr. Salazar shares her introduction to hysteroscopy and the mentors who shaped her early training. She discusses her expertise in hysteroscopic surgery and its broad applications, with a focus on the complexities of Asherman syndrome, dysmorphic uteri, and the critical role of endometrial health assessment. The conversation also covers surgical techniques, post-operative care, and emerging technologies in hysteroscopic and reproductive care. Dr. Salazar concludes by emphasizing the need for improved classification systems for Asherman syndrome and future directions in reproductive health innovation. --- TIMESTAMPS 00:00 - Introduction05:34 - Training and Mentorship in Hysteroscopy11:21 - Dr. Salazar's Practice and Techniques14:00 - Challenges and Trends in Surgical Practices18:58 - Referral Practices and Advanced Hysteroscopy21:58 - Understanding Dysmorphic Uterine Population24:08 - T-Shaped Uteri Description26:09 - Hysteroscopic Metroplasty: Methods and Risks29:17 - Innovations in Hysteroscopy32:38 - Value of Ultrasound in Hysteroscopy36:35 - Post-Operative Management and Estrogen Therapy39:23 - Challenges and Future Directions in Hysteroscopy44:23 - Concluding Thoughts --- RESOURCES The epidemiology, clinical burden, and prevention of intrauterine adhesions (IUAs) related to surgically induced endometrial trauma: a systematic literature review and selective meta-analyseshttps://academic.oup.com/humupd/article/31/6/588/8248883 Hysteroscopy Newsletterhttps://hysteroscopynewsletter.com/

Exercise during pregnancy has long been encouraged, but clear guidance on what actually drives measurable physiological benefits has often been inconsistent. Episode 6 of The Research Debrief unpacks a newly published systematic review and meta-analysis from the American Journal of Obstetrics and Gynecology examining how structured exercise training during pregnancy impacts maternal biomarkers. The conversation moves beyond general outcomes and dives into what the latest science says about inflamation, metabolism, hormones and immune function — and what that means for fitness operators serving pregnant members. This Episode Explores: - A new systematic review and meta-analysis examining how exercise training during pregnancy impacts maternal biomarkers - Why combining aerobic and resistance training produces the strongest physiological benefits - How moderate to vigorous intensity exercise influences inflammatory, metabolic and hormonal markers - The importance of program duration — and why interventions longer than 12 weeks matter - Practical guidelines for structuring prenatal programs in health club settings This episode provides operators with evidence-based clarity on how to confidently program for pregnant members, highlighting that structured, longer-duration aerobic and strength training can positively influence key maternal health markers — creating opportunities for safe, strategic and science-backed prenatal offerings within clubs.

today’s case, we are focusing on enslaved people, specifically WOMEN, that stood up against their caucus cuckolds and decided to do the KILLING instead of waiting to be killed.. SO JOIN US as we discuss the enslaved women that decided they’d HAD ENOUGH. RIP to the victims

As BMIs and weights increase across the US population, there have been increased calls for universal screening for existing DM at entrance to prenatal care, if under 20 weeks. Others, including the ACOG, prefer to screen early those with additional risk factors (like prior GDM HX, prior macrosomia, BMI >30, PCOS, first degree relative with diabetes, or age >40). In July 2024, the ACOG released its publication, “Screening for Gestational and Pregestational Diabetes in Pregnancy and Postpartum”. In this guidance, it states, “At this time, there are insufficient data to support the best screening modality for pregestational diabetes in pregnancy, but consideration can be made to use the same diagnostic criteria as for the nonpregnant population (A1c value 6.5 or higher, or fasting plasma glucose value 126 mg/dL or higher, or 2-hour plasma glucose value 200 mg/dL or higher during a 75-g OGTT, or random plasma glucose value 200 mg/dL or higher in patients with classic hyperglycemia symptoms)”. However, a new proposed protocol has been published in AJOG for early screening for DM in pregnancy. This also describes the differences in diagnosis and care for Standard GDM diagnosed at 24-28 weeks, vs a diagnosis of pregestational DM diagnosis made prior to 20-weeks vs “early” GDM also diagnosed under 20 weeks of gestation. Listen in for details. 1. McLaren, Rodney et al.nA Proposed Classification of Diabetes Mellitus in PregnancyAmerican Journal of Obstetrics & Gynecology, Volume 0, Issue 0. Epub Feb 2, 2026; https://www.ajog.org/article/S0002-9378(26)00061-X/fulltext2. ACOG Clinical Practice Update: Screening for Gestational and Pregestational Diabetes in Pregnancy and Postpartum; July 2024; https://journals.lww.com/greenjournal/abstract/2024/07000/acog_clinical_practice_update__screening_for.34.aspx3. Simmons, David et al. “Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy.” The New England journal of medicine vol. 388,23 (2023): 2132-2144. doi:10.1056/NEJMoa2214956

Learn how ACOG turns advocacy into action, supports clinicians, and creates community. Plus, get tips on how you can get involved. In this episode of BackTable OBGYN, Dr. Sivani Aluru from Endeavor Health in Chicago shares her journey and involvement with ACOG, from her medical school days to her current role as the national JFCAC Chair. --- SYNPOSIS Dr. Aluru describes her experiences on various task forces, including the ACOG 75th Anniversary Task Force, and emphasizes the importance of education, advocacy, and community within the organization. She offers insights into the challenges and benefits of participating in ACOG, provides tips for getting involved, and highlights the ongoing efforts to address critical issues in women's health. The conversation also touches on adapting to the changes brought by the COVID-19 pandemic and the value of staying organized and connected in a demanding field. Find out what ACOG is working on, how it benefits patient care, how it benefits provider education and resources, how it builds community. Get involved! Go to meetings! There are so many roles. If you don't get your role on the first go, try again. Showing up is huge! --- TIMESTAMPS 00:00 - Introduction03:41 - Residency and Early Involvement in ACOG07:29 - Advocacy and Government Affairs18:40 - Balancing Professional and Organizational Work24:28 - Listening to Members' Needs26:36 - Challenges and Value of ACOG Membership29:00 - The Importance of In-Person Meetings34:45 - ACOG's Legislative Advocacy and Future Plans35:48 - Advice for Getting Involved with ACOG40:16 - Conclusion --- RESOURCES ACOG (American College of Obstetricians and Gynecologists)https://www.acog.org/ ACOG CAARE Delegation https://www.acog.org/about/diversity-equity-and-inclusive-excellence/collective-action-strategy/caare-delegation ACOG CREOG (Council on Resident Education in Obstetrics and Gynecology) https://www.acog.org/education-and-events/creog/about

Guest: Lauren Osborne, M.D. Lauren Osborne, M.D., a reproductive psychiatrist at NewYork-Presbyterian and Weill Cornell Medicine and vice chair for clinical research for the Department of Obstetrics and Gynecology, discusses her research into the biological basis of postpartum depression. In a recent study, Dr. Osborne and her team were the first to analyze the entire metabolic pathway of progesterone, measuring both positive and negative allosteric modulators of the GABAA receptor throughout pregnancy and ultimately identifying a potential biomarker to predict risk. They are continuing to study and build upon these findings, with the goal of enabling better prediction and treatment options to address, or even prevent, postpartum depression. © 2026 NewYork-Presbyterian

In this episode, Dr. Margaret Larkins-Pettigrew, Professor and Academic Chair of Obstetrics and Gynecology at Drexel University School of Medicine, discusses closing gaps in maternal and child health, strengthening academic and healthcare partnerships, and addressing workforce shortages.

Pam Simon, MSN, CPNP, CPON, Stanford Adolescent and Young Adult Cancer Program (SAYAC), Palo Alto, CA and H. Irene Su, MD MSCE, University of California San Diego, San Diego, CA Recorded on January 20, 2026 Pam Simon, MSN, CPNP, CPON Nurse Practitioner & Program Manager Stanford Adolescent and Young Adult Cancer Program (SAYAC) Palo Alto, CA H. Irene Su, MD MSCE Professor Reproductive Endocrinology and Infertility Fellowship Director Division of Reproductive Endocrinology and Infertility Co-Director, Center for Obstetrics and Gynecology Research Innovations Department of Obstetrics, Gynecology and Reproductive Sciences Director, Moores Cancer Center Leadership Academy University of California San Diego San Diego, CA In this episode, we're joined by Dr. Irene Su, Professor of Obstetrics, Gynecology, and Reproductive Sciences at UC San Diego, and Pam Simon, Nurse Practitioner and Program Manager of the Stanford Adolescent and Young Adult (AYA) Cancer Program at Stanford Medicine. They discuss fertility risk across treatment types, approaches to fertility preservation and reproductive survivorship planning, insurance and access considerations, and the cultural and sociodemographic factors that shape care. They also share strategies to support shared decision-making and promote psychosocial well being for AYA patients and survivors. Tune in for practical insights to strengthen your approach to fertility care for AYAs. Mentioned on this episode: OncofertilityRisk.com The Alliance for Fertility Preservation Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

Join me and my guest Jamie Knopman, MD, a board certified reproductive endocrinologist and Director of Fertility Preservation for CCRM Fertility of New York. She is also Assistant Clinical Professor in Obstetrics and Gynecology at Mount Sinai Hospital. We explore the intersection of fertility, career-building, and personal agency and why equitable access to egg freezing is essential to gender equality in the workplace and beyond. Jamie brings not only deep clinical expertise, but also a culturally sharp, unapologetically feminist perspective on why women shouldn't have to choose between thriving professionally and preserving their future ability to have children. Nearly 70% of her patients today are freezing eggs before they face infertility. And companies such as Meta, Disney, and Amazon often cover the cost. She also highlights new pathways like egg-sharing programs that allow women to preserve their fertility at no cost, if they choose to donate a portion of their eggs. These trends reflect a cultural shift, and one she believes we urgently need to accelerate. SHOW NOTES  SPONSORED BY: Power of You! https://leader.blainebartlett.com/power-of-you Summary In this conversation, Blaine and Dr. Jamie Knopman discusses the evolving landscape of fertility, particularly focusing on egg freezing and embryo preservation. She highlights the importance of education and empowerment for women in making informed choices about their reproductive health. The discussion also touches on the emotional dynamics surrounding fertility, the role of companies in supporting women's choices, and future innovations in fertility medicine. Dr. Knopman emphasizes the need for a supportive work environment that recognizes the unique challenges women face in balancing career and family planning.   Takeaways The shift from infertility to fertility preservation is significant. Egg freezing allows women to maintain reproductive autonomy. Companies are increasingly offering fertility benefits to attract talent. Emotional dynamics play a crucial role in fertility decisions. Work-life balance requires planning and support systems. Education about fertility is essential for informed choices. Women are empowered to take charge of their reproductive health. Future innovations in fertility medicine are promising. The journey of life is fluid and not linear. Supportive work environments enhance women's contributions. Learn more about your ad choices. Visit megaphone.fm/adchoices

We have learned a lot about extended spectrum coverage of prophylactic antibiotics for cesarean section. The landmark C/SOAP trial randomized 2,013 women undergoing nonelective cesarean delivery to azithromycin 500 mg IV plus standard prophylaxis versus placebo, demonstrating a 51% reduction in the composite outcome of endometritis, wound infection, or other infection. Adjuvant Zmax (plus standard first-generation cephalosporin) is now recognized as evidence-based antibiotic coverage for intrapartum cesarean, cesarean with ruptured membranes, and patients with obesity. This last patient characteristic comes from the ERAS latest update. But what is ZMAX is not available? Is there an evidence-based peri-op alternative in these cases? Does Gent and Clinda cover mycoplasma/Ureaplasma? What about postop flagyl? Listen in for details. 1. Tita AT, Szychowski JM, Boggess K, et al. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. The New England Journal of Medicine. 2016. 2. Yang M, Yuan F, Guo Y, Wang S. Efficacy of Adding Azithromycin to Antibiotic Prophylaxis in Caesarean Delivery: A Meta-Analysis and Systematic Review. International Journal of Antimicrobial Agents. 2022. 2. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstetrics and Gynecology. 2018. Committee on Practice Bulletins-Obstetrics 3. Martingano D, Nguyen A, Nkeih C, Singh S, Mitrofanova A. Clarithromycin Use for Adjunct Surgical Prophylaxis Before Non-Elective Cesarean Deliveries to Adapt to Azithromycin Shortages in COVID-19 Pandemic. PloS One. 2020. 4. Valent AM, DeArmond C, Houston JM, et al. Effect of Post–Cesarean Delivery Oral Cephalexin and Metronidazole on Surgical Site Infection Among Obese Women: A Randomized Clinical Trial. The Journal of the American Medical Association. 2017. 5. Wood, G. E., et al. "In Vitro Susceptibility of Mycoplasma genitalium to Nitroimidazoles." Antimicrobial Agents and Chemotherapy 6. https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm

Welcome to Perimenopause WTF!, brought to you by ⁠Perry⁠—the #1 perimenopause app and safe space for connection, support, and new friendships during the menopause transition. You're not crazy, and you're not alone!  Download the free Perry App on ⁠Apple⁠ or ⁠Android⁠ and join our live expert talks, receive evidence-based education, connect with other women, and simplify your perimenopause journey.Today's episode is titled “Motherhood Reloaded: Perimenopause, Hormones, and the Path Back to Yourself” with Dr. Fenske, Beth Crosby, Dr. Sameena Rahman. In this episode we discuss the challenges of motherhood whilst in Perimenopause. Tune in as our experts answer the Perry Community's questions; from wild emotions to getting enough sleep to the benefits of testosterone! This is the motherload of familiar situations and great advice. 

Dr. Rupsa Boelig, a 2025 March of Dimes Discovery Research Grant winner and an Associate Professor of Obstetrics and Gynecology in the Division of Maternal Fetal Medicine at Philadelphia's Thomas Jefferson University, discusses her new study on the metabolism of aspirin in pregnant women with diabetes or a higher BMI. She hopes the study findings will shed light on whether these women may benefit from a higher aspirin dose to help prevent preeclampsia and/or preterm birth.

As OB healthcare providers, we have several pieces of guidance regarding determination of amniotic fluid volume antepartum. The SMFM has Consult Series #46 (2018), which describes the management of polyhydramnios. We'll touch on that in this episode. However, while we have clear understanding of the increased risks of oligohydramnios, where an MVP is preferred for diagnosis over AFI, we have less information about polyhydramnios. But a new study published in BJOG (January 2026) provides more insights on this. While MVP is preferred for oligo diagnosis, can the same be said for polyhydramnios? Is there an increased risk in perinatal morbidity with polyhydramnios, and is that better detected by MVP or AFI? This new study findings left the authors unsatisfied although it CONFIRMED what we have covered in past episodes. Listen in for details.1. Dashe, Jodi S. et al. SMFM Consult Series #46: Evaluation and management of polyhydramnios. American Journal of Obstetrics & Gynecology, Volume 219, Issue 4, B2 - B8 (2018)2. ACOG PB 229: Antepartum Fetal Surveillance (2021)3. Petrecca A, Chauhan SP, Tersigni C, Ghi T, Berghella V. Amniotic Fluid Index Versus Maximum Vertical Pocket Versus Both for Polyhydramnios. BJOG. 2026 Jan 7. doi: 10.1111/1471-0528.70139. Epub ahead of print. PMID: 41502220.

Back in March of 2025, the green journal (obstetrics andgynecology) published A systematic review and meta-analysis on 2 medications (non-hormonal) and their efficacy in menopausal hot flash relief period these medications were Fezolinetant and Elinzanetant. However, the editors have just recently released an “Expression of Concern” about this review. Listen in for details. 1.     Menegaz de Almeida, Artur MS; Oliveira, PalomaMS; Lopes, Lucca MD; Leite, Marianna MS; Morbach, Victória MS; Alves Kelly,Francinny MD; Barros, Ítalo MS; Aquino de Moraes, Francisco Cezar MS;Prevedello, Alexandra MD. Fezolinetant and Elinzanetant Therapy for MenopausalWomen Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.Obstetrics & Gynecology 145(3):p 253-261, March 2025. | DOI:10.1097/AOG.00000000000058122.     Expression of Concern: Fezolinetant andElinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: ASystematic Review and Meta-Analysis. Obstetrics & Gynecology():10.1097/AOG.0000000000006180, January 16, 2026. | DOI: 10.1097/AOG.0000000000006180

Implanon (etonogestrel implant) first received FDA approval in 2006, followed by the improved, radiopaque version, Nexplanon, approved by the FDA in 2010, which is now the only contraceptive implant available in the U.S. It was originally FDA approved for a 3-year use duration, although peer reviewed clinical data had demonstrated efficacy through year 5. Now, as of January 2026, the FDA has formally agreed to extend the label for 5-year use. In this episode, we will review the clinical data that prompted the FDA's decision, based on a multicenter, single-arm, open-label study evaluating contraceptive efficacy and safety during years 4 and 5 of implant use.1. https://www.contemporaryobgyn.net/view/fda-approves-5-year-use-for-etonogestrel-implant-68-mg-contraceptive2. Organon announces US Food and Drug Administration approval of supplemental new drug application extending duration of use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque. Organon. Press release. January 16, 2026. Accessed January 19, 2026. https://www.organon.com/news/organon-announces-us-food-and-drug-administration-approval-of-supplemental-new-drug-application-extending-duration-of-use-of-nexplanon-etonogestrel-implant-68-mg-radiopaque/3. Ali M, Akin A, Bahamondes L, et al. Extended Use Up to 5 Years of the Etonogestrel-Releasing Subdermal Contraceptive Implant: Comparison to Levonorgestrel-Releasing Subdermal Implant. Human Reproduction. 2016. 4. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged Use of the Etonogestrel Implant and Levonorgestrel Intrauterine Device: 2 Years Beyond Food and Drug Administration-Approved Duration. American Journal of Obstetrics and Gynecology. 2017. 5. McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the Etonogestrel Implant and Levonorgestrel Intrauterine Device Beyond the U.S. Food and Drug Administration-Approved Duration. Obstetrics and Gynecology. 2015.

What if maternal health goals expanded beyond "alive and healthy"? In honor of Maternal Health Awareness Day, Debra Pascali-Bonaro invites us to imagine a world where pregnancy, birth, and postpartum care are not only safe but also deeply respectful, emotionally whole, and infused with comfort and pleasure. In this moving solo episode, Debra shares her personal connection to the origins of Maternal Health Awareness Day—beginning in her home state of New Jersey—and explores how far the movement has come, and how far we still must go. With maternal mortality rates rising across the U.S. and nearly 80% of pregnancy-related deaths proven preventable, Debra calls us to collective action: to hold ground, raise our voices, and reclaim maternal health as a human right. From advocacy and policy to embodied care and global collaboration, this episode invites you to consider: what does it mean to move from surviving to thriving with safety, love, and pleasure? In this episode, you'll learn: The origins of Maternal Health Awareness Day and its urgent mission. Why systemic inequities—not personal failures—drive maternal mortality rates. How safety, equity, and pleasure are biologically connected in birth. The protective power of respect, love, and support during birth and postpartum. Practical advocacy steps for expectant parents, birth workers, and allies. Mentioned in this episode: International MotherBaby Childbirth Organization  @internationalmotherbabychi3946   International Childbirth Initiative (ICI)  @internationalchildbirthini2273   FIGO (International Federation of Gynecology and Obstetrics)  ICM (International Confederation of Midwives)  @WorldMidwives   American College of Obstetricians and Gynecologists (ACOG)   Eat Pray Doula Advanced Retreats www.eatpraydoula.com  Pleasurable Birth Essentials https://www.orgasmicbirth.com/pleasurable-birth-essentials Resources & Next Steps: Learn more and access free resources at https://www.orgasmicbirth.com/black-maternal-health-birth-equity-resources Share how you're holding ground on maternal health using #OrgasmicBirth and tag @orgasmicbirth on social media. Review and follow the show—we'd love to hear how this episode inspired you! Connect with Debra! Website: https://www.orgasmicbirth.com Instagram:   / orgasmicbirth  X:   / orgasmicbirth   YouTube    / orgasmicbirth1   Tik Tok   / orgasmicbirth   LinkedIn:   / debra-pascali-bonaro-1093471    ----

Decisions about family planning rarely happen in isolation. In the U.S., access to contraception, fertility care, and pregnancy-related services is shaped not only by individual choice, but by partners, families, employers, health care systems, and state policy—factors that can dramatically influence reproductive outcomes. Research consistently shows that social and structural conditions play a defining role in who can plan a pregnancy, delay one, or receive timely care. In the social domain of family planning, Kirtly Jones, MD, and Katie Ward, PhD, are joined by Jessica Sanders, PhD, assistant professor of Obstetrics and Gynecology and Director of Research at the ASCENT Center for Reproductive Health. Together, they explore how family planning decisions are shaped by layers of influence—from intimate partner dynamics and community access to poverty, misinformation, and shifting laws. The conversation examines how social forces enter even the most private decisions, and why understanding these pressures is essential for supporting truly informed, equitable reproductive care.

Ursodiol (ursodeoxycholic acid) is a prescription bile acid medication used to dissolve cholesterol gallstones, prevent gallstones during rapid weight loss, and treat liver diseases like primary biliary cholangitis (PBC) by reducing toxic bile acids and cholesterol production. It works by changing bile composition, making it less saturated with cholesterol, and is available as oral medication. Of course, it is also the foundational medication for treatment of diagnosed Intrahepatic Cholestasis of Pregnancy (ICP). Does this medication reduce adverse perinatal outcomes? In this episode, we will review a new study from the Green Journal, which will be out in February 2026, examining the recurrence risk for ICP using data from NY. In a patient with prior history of ICP, is there any guidance on monitoring of serum bile acids in the subsequent pregnancy before symptoms develop? We will explain. PLUS we will review the data on whether Ursodiol may hold promise in recurrence prevention or in reduction of adverse outcomes once the condition is diagnosed. Listen in for details. 1. 2019: Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH, Chambers J, Hunter R, Dorling J, Williamson C, Thornton JG; PITCHES study group. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019 Sep 7;394(10201):849-860. doi: 10.1016/S0140-6736(19)31270-X. Epub 2019 Aug 1. PMID: 31378395; PMCID: PMC6739598. https://pubmed.ncbi.nlm.nih.gov/31378395/2. February 08, 2025: Rahim, Mussarat N et al. Pregnancy and the liver. The Lancet. 2021; Volume 405, Issue 10477, 498 – 513 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02351-1/fulltext3. SMFM CS 53; 20214. Rosenberg, Henri M. MD; Sarker, Minhazur R. MD; Ramos, Gladys A. MD; Bianco, Angela MD; Ferrara, Lauren MD; DeBolt, Chelsea A. MD. Intrahepatic Cholestasis of Pregnancy Recurrence in a Subsequent Pregnancy. Obstetrics & Gynecology 147(2):p 239-241, February 2026. | DOI: 10.1097/AOG.0000000000006033 https://journals.lww.com/greenjournal/fulltext/2026/02000/intrahepatic_cholestasis_of_pregnancy_recurrence.13.aspx5. Ovadia C, Sajous J, Seed PT et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2021 Jul;6(7):547-558. doi: 10.1016/S2468-1253(21)00074-1. Epub 2021 Apr 27. PMID: 33915090; PMCID: PMC8192305.6. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. European Association for the Study of the Liver; 2023

Feeling exhausted, foggy, short of breath, or just not like yourself during pregnancy and being told “that's normal”? This episode is for you. In Episode 417 of The Birth Lounge, HeHe sits down with OB/GYN PA and public health expert Kristy Goodman to talk about anemia in pregnancy and why it's so often overlooked, minimized, or brushed off until it becomes a much bigger issue. Together, they break down what anemia actually is, how and when it should be screened for, and why catching it early can completely change how you feel during pregnancy, labor, and postpartum. They explore how untreated anemia can impact energy levels, labor stamina, recovery, and overall well-being, and more importantly, what becomes possible when it's properly identified and treated with intention. Think more clarity, more strength, better healing, and the confidence to advocate for yourself instead of second-guessing your symptoms. Kristy brings an evidence-based, patient-centered lens to this conversation, helping listeners understand what labs matter, what questions to ask their provider, and how to push back when concerns are dismissed as “just part of pregnancy.” This episode is grounding, empowering, and deeply validating. If you've ever felt brushed off, unsure whether what you're feeling is normal, or just want to feel stronger and more supported in your body, this conversation will give you real tools and real answers.

Tara Eicher is a postdoctoral research fellow in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. T. Eicher, J. Quackenbush, and A. Ne'eman. Challenging Claims of an Autism Epidemic — Misconceptions and a Path Forward. N Engl J Med 2026;394:313-315.

Behind the Knife ABSITE 2026 – Up-to-date and high yield learning to help you DOMINATE the exam.Don't forget to check out our ABSITE Podcast Companion Book available on Amazon: https://www.amazon.com/Behind-Knife-ABSITE-Podcast-Companion/dp/B0CLDQWZG3/ref=monarch_sidesheetBe sure to check out our free study aid, which includes all 32 review episodes, brief written summaries, high yield images, and flash cards. Simply create an account on our iOS or Android app or on our website and you will find the entire course in your Library. Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Google Play App Store: https://play.google.com/store/apps/details?id=com.btk.appBehind the Knife would like to sincerely thank Medtronic for sponsoring the entire 2026 ABSITE podcast series.  Medtronic has a rich history of supporting surgical education, and we couldn't be happier that they chose to partner with Behind the Knife.  Learn more at https://www.medtronic.com/en-us/index.htmlIf you like the work that Behind the Knife is doing, please leave us a review wherever you listen to podcasts.  Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  Check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewBehind the Knife in Español - repaso para el examen de certificación en cirugía general: https://app.behindtheknife.org/premium/repaso-para-el-examen-de-certificaci-n-en-cirug-a-general

The ENG implant has data placing it as the most reversible, hormonal contraceptive agent available with a typical use failure rate of 0.05%. Unfavorable bleeding patterns, such as frequent or prolonged bleeding, affect approximately 40% of ENG implant users within the first 3 months but typically improve over time. Nonetheless, it is the main reason for patient discontinuation. In the past, various medications have shown to have at least some short-term reduction in bothersome breakthrough bleeding (BTB). These include doxycycline, ethinyl estradiol (EE), mefenamic acid, combined oral contraceptives (COCs), short term tamoxifen, norethindrone, and ulipristal acetate. In this episode, we will summarize a new RCT (AJOG, released as epub on Jan 7, 2026) which describes the use of TXA for ENG related BTB. Did it work? Listen in for details.1. Andrade, Maíra Cristina Ribeiro et al. Norethisterone for prolonged uterine bleeding associated with etonogestrel implant (IMPLANET): a randomized controlled trialAmerican Journal of Obstetrics & Gynecology, Volume 234, Issue 1, 101 - 1152. Edelman, Alison et al. Treatment of unfavorable bleeding patterns in contraceptive implant users with tranexamic acid: randomized clinical trial. American Journal of Obstetrics & Gynecology, Volume 0, Issue (Articles in Press January 07, 2026)

In vitro fertilization, or IVF, can cost upwards of $20,000 in California — for one cycle. For that reason, it's put financial strain on many California families and been completely out of reach for others, including couples who have faced insurance denials because they are LGBTQ+. But a California law that went into effect this month, SB 729, requires large employer-sponsored health plans to cover up to three cycles of IVF, along with other infertility services, regardless of sexual orientation. We'll hear what the new law means for family planning in California, and for you: Does this put IVF within reach for you? What's been your experience with IVF? Guests: Caroline Menjivar, member of the California State Senate representing the 20th district (San Fernando Valley) Shefali Luthra, reproductive health reporter, The 19th Sarah Jolly, has been trying to conceive with her husband for five years Dr. Alexander Quaas, medical director Shady Grove Fertility San Diego; fertility specialist; wrote an article for the American Journal of Obstetrics & Gynecology titled, “The California infertility insurance mandate: another step toward reproductive justice?” Learn more about your ad choices. Visit megaphone.fm/adchoices

If you go by pop culture depictions, menopause seems like no big deal — a few hot flashes, some comical bouts of hormone-fueled rage, and the “big change,” as it was once called, is over. But for many of the 2 million American women who enter menopause each year, the symptoms can be a lot more serious and long-lasting, ranging from vertigo and joint pain to brain fog and heart problems.On this episode, we take a deep dive into perimenopause and menopause – what's going on biologically? What can be done to ease symptoms? And why do so many women struggle to receive help from their doctors?We talk with menopause experts about hormone replacement therapy, and why it was demonized for many years; find out what researchers have discovered about the causes of brain fog; and hear about new efforts to deal with medically induced menopause. In this excerpt from our live event, Reimagining Menopause, host Maiken Scott talks with two certified menopause providers — Robyn Faye, an OB-GYN at Jefferson Health in Philadelphia, and Arina Chesnokova, assistant professor in of Obstetrics and Gynecology at the University of Pennsylvania's Perelman School of Medicine — about the ins and outs of hormone therapy, which symptoms it alleviates, when it's safe and when it's not. Watch the full discussion here. Reporter Alan Yu talks with researchers about what's behind one of the most vexing symptoms of menopause for many women — brain fog. For women who have cancer when they're younger, especially breast or ovarian cancer, chemotherapy and other medications needed to treat the disease can affect hormones - and suddenly plunge them into menopause, years before they might naturally experience it. We explore what their options are, and why so many say they were not prepared for this change.

A Podcast from Obstetrics & Gynecology highlighting the latest research and practice updates in the field. This episode features an interview with Dr. Ann Oluloro, author of "Association Between Comorbidity and Clinical Trial Enrollment for Patients With Uterine Cancer."

It's a controversial topic: the impact of uterine incision (hysterectomy) on the neonate delivery interval (also called the U-D interval). Does it matter? Just to be clear, we're talking about time from uterine entry to fetal extraction, not skin incision to fetal extraction. Past publications have produced conflicting results, often limited by small sample sizes, heterogeneous indications for delivery, and reliance on surrogate markers (like apgar scores) rather than clinical morbidity. But a new study published in the Gray journal at the end of 2025 (December 30, 2025) gives some new insights. In this episode, we will review this retrospective study and play the “Devil's advocate” as we summarize the rebuttal data. As the reports are conflicting, we will end the podcast with a real-world interpretation and application of this data. Listen in for details. 1. Bart, Yossi et al. Uterine Incision-to-Delivery Interval and Neonatal Outcomes among Non-urgent, Term, Cesarean Deliveries. American Journal of Obstetrics & Gynecology, Volume 0, Issue 0. https://www.ajog.org/article/S0002-9378(25)00980-9/fulltext?rss=yes2. Maayan-Metzger A, Schushan-Eisen I, Todris L, Etchin A, Kuint J. The effect of time intervals on neonatal outcome in elective cesarean delivery at term under regional anesthesia. Int J Gynaecol Obstet. 2010 Dec;111(3):224-8. doi: 10.1016/j.ijgo.2010.07.022. Epub 2010 Sep 19. PMID: 20855070. https://pubmed.ncbi.nlm.nih.gov/20855070/3. Spain JE, Tuuli M, Stout MJ, Roehl KA, Odibo AO, Macones GA, Cahill AG. Time from uterine incision to delivery and hypoxic neonatal outcomes. Am J Perinatol. 2015 Apr;32(5):497-502. doi: 10.1055/s-0034-1396696. Epub 2014 Dec 24. PMID: 25539409.4. Bader AM, Datta S, Arthur GR, Benvenuti E, Courtney M, Hauch M. Maternal and fetal catecholamines and uterine incision-to-delivery interval during elective cesarean. Obstet Gynecol. 1990 Apr;75(4):600-3. PMID: 2107478.5. Tekin, E., Inal, H.A. & Isenlik, B.S. A Comparison of the Effect of Time from Uterine Incision to Delivery on Neonatal Outcomes in Women with One Previous and Repeat (Two or More) Cesarean Sections. SN Compr. Clin. Med. 5, 80 (2023). https://doi.org/10.1007/s42399-023-01427-x

In this conversation, Dr. Tomer Singer shares his personal journey into reproductive medicine, influenced by his family's struggles with infertility. He discusses the unique challenges faced by Orthodox couples in fertility treatments and the importance of community engagement. The conversation also covers the rise of egg freezing as a viable option for women, the optimal age for freezing eggs, and the success rates of frozen eggs. Dr. Singer emphasizes the role of nutrition and AI in improving patient care and outcomes in reproductive medicine. He concludes with thoughts on the future of fertility treatments.Chapters00:00 The Journey into Fertility Medicine02:50 Understanding Orthodox Fertility Practices05:39 Navigating Religious and Medical Collaboration08:54 Education and Communication in Fertility11:40 The Rise of Egg Freezing15:01 Optimal Age for Egg Freezing17:58 Success Rates of Frozen Eggs20:39 Improving Egg Quality and Patient Health23:59 Future of Egg Freezing Technology29:51 Understanding the Costs of Egg Freezing32:59 The Importance of Egg Freezing for Future Fertility34:08 The Age Visit: A New Approach to Women's Health38:18 The Role of AI in Reproductive Medicine41:25 Job Security in the Age of AI45:23 Future Trends in Fertility Treatments48:46 Rapid Fire Questions on Fertility Practices52:28 Prioritizing Mental Health in a Busy Life54:25 Connecting with Dr. SingerAbout Dr. Tomer Singer:Tomer Singer, MD, MBA is an internationally renowned Endocrinologist and Infertility Specialist. He serves as the System Chief of Reproductive Endocrinology and Infertility at Northwell Health where he is responsible for programmatic strategy and fosters academic and clinical growth. Dr. Singer earned his medical degree from the Sackler School of Medicine and an MBA in Health Care Management from the Hofstra Zarb School of Business. He is double board- certified in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility. He is an Associate Professor of OB/GYN at the Donald and Barbara Zucker School of Medicine. Dr. Singer has produced numerous publications, chapter reviews, and given presentations nationally and internationally in the field of Infertility, Reproductive Endocrinology, IVF, Pre-Implantation Genetic Testing (PGT), Egg Freezing, Egg Donation, and Gestational Surrogacy. He has performed hundreds of minimally invasive surgical procedures including laparoscopies and hysteroscopies. Dr. Singer has held several senior roles at Lenox Hill Hospital where he served as the Director of Reproductive Endocrinology and Infertility, the Vice Chairman of the Department of OB/GYN, Director of Egg Freezing, and the OB/GYN Residency Program Director. Dr. Singer's commitment to helping thousands of patients has earned him several awards including the Castle Conolly Top Doctor Award every year since 2017. Contact Dr. Tomer SingerInstagram @tsingermd

Doctors have long recommended regular cervical cancer screenings. Traditionally doctors perform these exams using a speculum, which often say is uncomfortable and, for many, quite painful. Some recent developments could make a large number of these screenings easier. In early January, the Health Resources and Services Administration, which is part of the Department of Health and Human Services, updated its guidelines to say that self-administered tests are an acceptable way to screen for human papillomavirus. HPV is a sexually-transmitted disease that causes the majority of cervical cancer cases. OB-GYNs are hopeful that at-home testing will make cervical cancer screenings easier to access…. and significantly more comfortable. Guests: Dr. Linda Eckert, professor of Obstetrics and Gynecology at the University of Washington School of Medicine Related links: New Guidelines Endorse Self-Swab Alternative to Pap Smear for Cervical Cancer Testing - The New York Times Cervical Cancer Risk Factors | Cervical Cancer | CDC The FDA has approved an at-home HPV test. What you need to know : NPR Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

In this episode of Parts and Labor, Angela Chaudhari, MD, hosts a panel of experts from Northwestern Medicine's Division of Gynecologic Oncology to discuss the groundbreaking research and clinical trials shaping the future of gynecologic cancer care. The panel explores innovations in immunotherapy, investigator-initiated trials, survivorship and symptom science, while highlighting efforts to expand access and diversity in clinical research across Chicago and the surrounding suburbs.This episode's panel of guests includes:• Emma L. Barber, MD, John and Ruth Brewer Professor of Gynecology and Cancer Research, Division Chief of Gynecologic Oncology and Director of Robotic Surgery• Daniela E. Matei, MD, Diana, Princess of Wales Professor of Cancer Research and Chief of Reproductive Science in the Departments of Obstetrics and Gynecology and Hematology and Oncology• Dario R. Roque, MD, Associate Professor of Gynecologic Oncology and Fellowship Program Director• Emily M. Hinchcliff, MD, Assistant Professor of Gynecologic Oncology and Program Director of the OB-GYN Residency Program

Skin Deep: How Melanin Impacts Your Body's Response To DrugsScientific research is becoming more inclusive, but one area that's still lacking this diversity is pre-clinical research. Without knowing how medications will react to different ancestries and skin tones, millions of people are being put at risk. Our experts discuss the effect melanin has on a drug's efficacy and changes the industry can implement right now that will make a big difference.  Does Birth Control Cause PCOS? Facts And Misconceptions Of The Disorder  Polycystic ovarian syndrome affects at least one in ten women – probably more since it's so underdiagnosed. Sadly, many women are told that having PCOS means they'll never become pregnant. However, our expert this week dispels this and other misinformation that's widespread about PCOS.  Medical Notes: Robots Are Outperforming Doctors, The Dangerous Additives In Ultra-Processed Foods, And How Happiness Supports Your Brain HealthHow scientists could catch Schizophrenia sooner than ever before. Ultra-processed foods may be raising your blood sugar levels. How happiness supports your brain health. Are robots better doctors? Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Does Birth Control Cause PCOS? Facts And Misconceptions Of The Disorder  Polycystic ovarian syndrome affects at least one in ten women – probably more since it's so underdiagnosed. Sadly, many women are told that having PCOS means they'll never become pregnant. However, Dr. Lora Shahine dispels this and other misinformation that's widespread about PCOS.  Host: Greg Johnson.  Producers: Kristen Farrah.  Guests: Dr. Lora Shahine, Double Board-Certified Reproductive Endocrinologist and Infertility Specialist, Pacific Northwest Fertility, Podcast Host, Baby or Bust Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Uterine rupture or dehiscence associated with TOLAC results in the most significant increase in the likelihood of additional maternal and neonatal morbidity. It should be noted that the terms “uterine rupture” and “uterine dehiscence” are not consistently distinguished from each other in the literature and often are used interchangeably. Furthermore, the reported incidence of uterine rupture varies in part because some studies have grouped true, catastrophic uterine rupture together with asymptomatic scar dehiscence. In January 2026, a new meta-analysis examines the relationship between oxytocin use with TOLAC and uterine rupture. In this episode, we will summarize the key findings in that study and review the data on the use of internal monitors during TOLAC. Do internal monitors (FSE, IUPC) offer a safer TOLAC compared with external monitors? Listen in for details.1. Nicolì, Pierpaolo et al.Oxytocin dosing during trial of labor after cesarean to minimize the risk of uterine rupture: a systematic review and meta-analysisAmerican Journal of Obstetrics & Gynecology MFM, Volume 8, Issue 1, 1018462. Practice Bulletin No. 184: Vaginal Birth After Cesarean Delivery. Obstetrics & Gynecology 130(5):p e217-e233, November 2017. | DOI: 10.1097/AOG.00000000000023983. ACOG Clinical Practice Guideline No. 10:Intrapartum Fetal Heart Rate Monitoring: Interpretation and Management. Obstetrics & Gynecology 146(4):p 583-599, October 2025. | DOI: 10.1097/AOG.00000000000060494. Bruno AM, Allshouse AA, Metz TD. Maximum Oxytocin Dose and Uterine Rupture During Trial of Labor After Cesarean. Obstet Gynecol. 2025 Dec 1;146(6):843-850. doi: 10.1097/AOG.0000000000006106. Epub 2025 Oct 30. PMID: 41325062.

In this episode, Dr. Blythe Bynum joins the show to discuss her new article titled Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder, featured in the November/December issue of the Journal of Addiction Medicine. Dr. Blythe Bynum is an assistant professor in the Department of Obstetrics and Gynecology at Thomas Jefferson University in Philadelphia, Pennsylvania. She is a board certified OBGYN with fellowship training in Complex Family Planning.    Article Link: Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder

In 2002, the National Institute of Child Health and Human Development (NICHD) proposed the 3-Tier fetal heart rate (FHR) classification system that was subsequently adopted by many organizations, categorizing tracings into three groups: Category I (normal), Category II (indeterminate), and Category III (abnormal). Recently, our podcast team received an interesting question form one of our podcast family members: “If there is a change in the fetal heart rate tracing intrapartum, but it is still in the normal range (like 120 going to 150)- and variability is normal, is that an abnormality? And what is meant by a ‘ZigZag' FHT pattern (different than marked variability)?”. That is a fantastically complex question…and we will explain the answer in this episode.1. Zullo F, Di Mascio D, Raghuraman N, Wagner S, Brunelli R, Giancotti A, Mendez-Figueroa H, Cahill AG, Gupta M, Berghella V, Blackwell SC, Chauhan SP. Three-tiered fetal heart rate interpretation system and adverse neonatal and maternal outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023 Oct;229(4):377-387. doi: 10.1016/j.ajog.2023.04.008. Epub 2023 Apr 11. PMID: 37044237.2. Ghi T, Di Pasquo E, Dall'Asta A, et al. Intrapartum Fetal Heart Rate Between 150 and 160 BPM at or After 40 Weeks and Labor Outcome.Acta Obstetricia Et Gynecologica Scandinavica. 2021;100(3):548-554. doi:10.1111/aogs.14024.3. The 3 Tier System: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://ncc-efm.org/filz/NICHD_Reference_from_CCPR.pdf4. Jia YJ, Ghi T, Pereira S, Gracia Perez-Bonfils A, Chandraharan E. Pathophysiological Interpretation of Fetal Heart Rate Tracings in Clinical Practice. American Journal of Obstetrics and Gynecology. 2023;228(6):622-644. doi:10.1016/j.ajog.2022.05.0235. Ghi T, Di Pasquo E, Dall'Asta A, et al. Intrapartum Fetal Heart Rate Between 150 and 160 BPM at or After 40 Weeks and Labor Outcome. Acta Obstetricia Et Gynecologica Scandinavica. 2021;100(3):548-554. doi:10.1111/aogs.14024.6. Yang M, Stout MJ, López JD, Colvin R, Macones GA, Cahill AG. Association of Fetal Heart Rate Baseline Change and Neonatal Outcomes. Am J Perinatol. 2017 Jul;34(9):879-886. doi: 10.1055/s-0037-1600911. Epub 2017 Mar 16. PMID: 28301895.

Podcast Family, in our immediate past episode we tackled the discrepancy that is often found between a clinical diagnosis of intra-amniotic infection/chorioamnionitis and histological chorioamnionitis. From that episode, we received a fantastic question from one of our podcast family members: Can a patient have IAI without fever? That question is really deep and highlights a gap in the current diagnostic scheme/ criteria from the ACOG. Listen in for details!1. ACOG CO 7122. Sukumaran S, Pereira V, Mallur S, Chandraharan E. Cardiotocograph (CTG) Changes and Maternal and Neonatal Outcomes in Chorioamnionitis and/­or Funisitis Confirmed on Histopathology. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2021. C3. Romero R, Chaemsaithong P, Korzeniewski SJ, et al. Clinical Chorioamnionitis at Term III: How Well Do Clinical Criteria Perform in the Identification of Proven Intra-Amniotic Infection? Journal of Perinatal Medicine. 2015.

Episode: 2834 Wombs and Witchcraft: Edward Jorden's Suffocation of the Mother (1603).  Today, wombs and witchcraft.

Major health organizations, including the CDC and ACOG, recommend universal Hepatitis C Virus (HCV) screening for all pregnant women during each pregnancy and at time of delivery. Ideally, pregnant women should be screened for hepatitis C virus infection at the first prenatal visit of each pregnancy. If the antibody screen result is positive, hepatitis C virus RNA polymerase chain reaction testing is done to confirm the diagnosis. The risk of perinatal transmission of HCV is up to 9%, with at least one-third of transmissions occurring antenatally. While antiviral therapy is recommended for Hepatitis B in pregnancy with a viral load greater than 200,000 international units/mL to decrease the risk of vertical transmission, the same is not the case for Hep C. According to the ACOG CPG #6 from September 2023, there are no standard treatment protocols for Hep C in pregnancy but a new publication from the PINK journal (7 Dec 2025) is calling for a change. That new publication is, “Hepatitis C Treatment During Pregnancy: Time for a Practice Change”. Listen in for details. 1. ACOG CPG #6; Sept 20262. Bhattacharya D, Aronsohn A, Price J, Lo Re V. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2023;:ciad319. doi:10.1093/cid/ciad319.3. Chappell CA, Kiser JJ, Brooks KM, et al. Sofosbuvir/¬Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2025;80(4):744-751. doi:10.1093/cid/ciae595.4. Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. The American Journal of Gastroenterology. 2022;117(10S):44-52. doi:10.14309/ajg.0000000000001960.5. Dutra, Karley et al. Hepatitis C Treatment During Pregnancy: Time for a Practice Change. American Journal of Obstetrics & Gynecology MFM, Volume 0, Issue 0, 1018656. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in Pregnancy-Updated Guidelines: Replaces Consult Number 43, November 2017. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Dotters-Katz SK, Kuller JA, Hughes BL. American Journal of Obstetrics and Gynecology. 2021;225(3):B8-B18. doi:10.1016/j.ajog.2021.06.008